Efficacy study on Dazhu Hongjingtian Injection combined with sacubitril valsartan sodium tablets in treatment of coronary heart disease compli-cated with heart failure
Objective To observe the efficacy of Dazhu Hongjingtian Injection combined with sacubitril valsartan sodium tablets in treatment of coronary heart disease complicated with heart failure(CHDWHF).Methods A total of 112 patients with CHDWHF were randomly divided into control group and treatment group,with 56 cases in each group.Control group was treated with sacubitril-valsartan sodium tablets,and treatment group was treated with Dazhu Hongjingtian Injection on the basis of control group.The total effective rate,TCM symptom score,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),N-terminal procursor brain natriuretic peptide(NT-proBNP),6-min walking distance(6 MWD),hematocrit,and platelet adhesion of the two groups were compared.The readmission rate and the serious cardiovascular adverse events were compared with HF exacerbation at 12 weeks of follow-up.Results After treatment,the total effective rate of treatment group was higher than that of control group(P＜0.05);the TCM symptom scores,LVESD,LVEDD,NT-proBNP,hematocrit and platelet adhesion in both groups were lower than those before treatment(P＜0.05),and were lower in treatment group than those in control group(P＜0.05);the LVEF and 6MWD in both groups were higher than those before treatment(P＜0.05),and were higher in treatment group than those in control group(P＜0.05);the readmission rate of HF deterioration and the incidence of serious cardiovascular adverse events in treatment group were lower than those in control group(P＜0.05).Conclusion Dazhu Hongjingtian Injection combined with sacubitril-valsartan sodium tablets can improve TCM symptoms and ventricular remodeling,improve cardiac function,improve hemodynamics,enhance efficacy,and reduce the readmission rate of HF deterioration and the incidence of serious cardiovascular adverse events in treatment of CHDWHF.
NETL
NSTL
万方数据
